Coronary disease & ACSMeta-analysis
Comparison of Limus and Paclitaxel Drug–Coated Balloons, Second-Generation or Newer Drug-Eluting Stents, and Balloon Angioplasty: A Network Meta-Analysis of Randomized Controlled Trials
- network meta-analysis of randomized controlled trials
Authors' conclusion
No significant differences were observed in MACE or its components between limus and paclitaxel DCBs, albeit with limited statistical power. Furthermore, DCB and second-generation or newer drug-eluting stents yielded similar outcomes though power was limited, especially for other de novo CAD.
Study context
- Population
- Patients with coronary artery disease (CAD)patients in 39 randomized controlled trials
- Participants
- 10,219 patients
- Comparison
- limus DCB, paclitaxel DCB, second-generation or newer drug-eluting stent, and plain old balloon angioplasty
- Outcome
- trial-defined major adverse cardiovascular events (MACEs), typically a composite of death, myocardial infarction, or target lesion revascularization
Pooled result
As reported in the abstract
Relative risk
1.22
95% CI 0.86–1.73
limus DCB vs paclitaxel DCB
relative risk 1.22 (95% CI 0.86–1.73)
Further pooled results
MACE in subgroups (in-stent restenosis, small-vessel CAD, other de novo CAD)
- Results consistent across subgroup analyses
Original publication
Comparison of Limus and Paclitaxel Drug–Coated Balloons, Second-Generation or Newer Drug-Eluting Stents, and Balloon Angioplasty: A Network Meta-Analysis of Randomized Controlled Trials. Circ Cardiovasc Interv. doi:10.1161/circinterventions.125.016005
Summarised from the published abstract; every number is checked against it